Skip to main content

ORAGENICS INC

For the period ended Mar 31, 2025. Filed May 9, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 9, 2025

OGEN$0.34-3.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

For the Three Months Ended March 31,
20252024
Cash flows from operating activities:
Net loss$(2,216,993)$(2,450,833)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and closing costs192,859-
Stock-based compensation expense17,70669,344
Stock-based compensation recapture expense(86,470)-
Changes in operating assets and liabilities:
Prepaid expenses and other current assets159,63711,061
Operating lease right of use assets-9,811
Accounts payable and accrued expenses(178,829)(693,821)
Change in operating lease liabilities-(9,811)
Net cash used in operating activities(2,112,090)(3,064,249)
Cash flows from financing activities:
Borrowings on short-term notes payable2,228,563-
Payments on short-term notes payable(195,565)(185,863)
Net proceeds from issuance of common stock2,635,3301,838,600
Net cash provided by financing activities4,668,3281,652,737
Net decrease in cash and cash equivalents2,556,238(1,411,512)
Cash and cash equivalents at beginning of period864,8403,483,501
Cash and cash equivalents at end of period$3,421,078$2,071,989
Supplemental disclosure of cash flow information:
Interest paid$6,268$7,085
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.